Adagene Inc. - ADS, each representing 1.25 ordinary shares (ADAG)
ADAG moved a median of +0.40% 30 minutes after news, and +0.77% by the close. How ADAG actually reacts to news — the realized, point-in-time move the market made, measured across 146 labeled events over the last three years with zero look-ahead.
ADAG’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 35% | 127 |
| 30-min | +0.40% | 54% | 137 |
| 60-min | +0.57% | 54% | 145 |
| to close | +0.77% | 58% | 144 |
| Middle 50% of ADAG reactions | -2.37% to +2.65% |
|---|---|
| Median reaction (30-min) | +0.40% |
| Measured reactions | 146 |
Half of all Adagene Inc. - ADS, each representing 1.25 ordinary shares news events land between -2.37% and +2.65% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ADAG reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 13 | -4.04% | 0% | -5.00% |
| Rating reiterations | 15 | 0.00% | 33% | -1.96% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how ADAG ranks against every other measured name →
That’s how ADAG usually reacts — get an email when it moves on news →Email me when ADAG moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ADAG's baseline. Nothing else.
Recent ADAG events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference | Press release | GlobeNewswire | -0.64% | -2.55% | |
| Form 6-K Adagene Inc. For: Sep 25 | SEC filing · Form 6-K | SEC EDGAR | +2.55% | +8.84% | |
| Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager | Press release | GlobeNewswire | -1.06% | -2.42% | |
| Form 6-K Adagene Inc. For: Sep 22 | SEC filing · Form 6-K | SEC EDGAR | -1.06% | -2.42% | |
| Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology | Press release | GlobeNewswire | -6.50% | -6.50% | |
| Form 6-K Adagene Inc. For: Sep 10 | SEC filing · Form 6-K | SEC EDGAR | -6.50% | -6.50% | |
| Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates | Press release | GlobeNewswire | -6.10% | -9.42% | |
| Form 6-K Adagene Inc. For: Sep 09 | SEC filing · Form 6-K | SEC EDGAR | -6.10% | -9.42% | |
| Adagene to Participate in Three Upcoming Investor Conferences | Press release | GlobeNewswire | -0.24% | -0.49% | |
| Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates | Press release | GlobeNewswire | -2.23% | -7.18% | |
| Form 6-K Adagene Inc. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -2.23% | -7.18% | |
| Form 6-K Adagene Inc. For: Jul 06 | SEC filing · Form 6-K | SEC EDGAR | -3.52% | -11.49% | |
| Adagene to Participate in Two Upcoming Investor Conferences | Press release | GlobeNewswire | +0.00% | -0.81% | |
| Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types | Press release | GlobeNewswire | +1.27% | -1.27% | |
| Form 6-K Adagene Inc. For: Apr 17 | SEC filing · Form 6-K | SEC EDGAR | +1.27% | -1.27% | |
| Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board | Press release | GlobeNewswire | +3.09% | -0.52% | |
| Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) | Press release | GlobeNewswire | +6.04% | +1.01% | |
| Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs | Press release | GlobeNewswire | +6.04% | +1.01% | |
| Form 6-K Adagene Inc. For: Apr 02 | SEC filing · Form 6-K | SEC EDGAR | +6.04% | +1.01% | |
| Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response | Press release | GlobeNewswire | +6.04% | +1.01% | |
| Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +6.04% | +1.01% | |
| Form 20-F Adagene Inc. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +6.04% | +1.01% | |
| Form 6-K Adagene Inc. For: Apr 01 | SEC filing · Form 6-K | SEC EDGAR | +6.04% | +1.01% | |
| Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA | Press release | GlobeNewswire | +0.00% | +0.77% | |
| Adagene to Participate in Two Upcoming Investor Conferences | Press release | GlobeNewswire | -3.18% | -4.91% | |
| BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsight | Press release | PR Newswire | +5.80% | +17.75% | |
| ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging | Press release | PR Newswire | +0.00% | +4.73% | |
| ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging | Press release | PR Newswire | — | +14.40% | |
| Adagene Provides Business Update and 2026 Objectives | Press release | GlobeNewswire | +0.98% | +22.66% | |
| Form 6-K Adagene Inc. For: Jan 23 | SEC filing · Form 6-K | SEC EDGAR | +0.98% | +22.66% | |
| Form EFFECT Adagene Inc. | SEC filing · Form EFFECT | SEC EDGAR | — | -6.47% | |
| Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126) | Press release | GlobeNewswire | -1.09% | +3.26% | |
| Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology | Press release | GlobeNewswire | -7.29% | — | |
| Form 6-K Adagene Inc. For: Nov 13 | SEC filing · Form 6-K | SEC EDGAR | -7.29% | — | |
| Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer | Press release | GlobeNewswire | -6.88% | -5.82% | |
| Form F-3 Adagene Inc. | SEC filing · Form F-3 | SEC EDGAR | +3.47% | +3.47% | |
| Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate | Press release | GlobeNewswire | -6.22% | -5.33% | |
| Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China | Press release | GlobeNewswire | +5.11% | +2.78% | |
| Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor | Press release | GlobeNewswire | +0.01% | +2.83% | |
| Adagene to Participate in Two Investor Conferences in September | Press release | GlobeNewswire | +2.21% | +0.85% | |
| Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates | Press release | GlobeNewswire | +7.89% | -13.16% | |
| Form 6-K Adagene Inc. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +7.89% | -13.16% | |
| Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA | Press release | GlobeNewswire | -5.47% | -1.04% | |
| Form 6-K Adagene Inc. For: Jul 15 | SEC filing · Form 6-K | SEC EDGAR | -5.47% | -1.04% | |
| Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate | Press release | GlobeNewswire | -1.01% | -4.54% | |
| Adagene announces up to $25 million strategic investment from Sanofi | Press release | GlobeNewswire | -1.97% | -8.87% | |
| Form 6-K Adagene Inc. For: Jul 01 | SEC filing · Form 6-K | SEC EDGAR | -1.97% | -8.87% | |
| Form EFFECT Adagene Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +12.70% | |
| Adagene to Present at Jefferies Global Healthcare Conference 2025 | Press release | GlobeNewswire | +0.00% | +5.83% | |
| Form F-3/A Adagene Inc. | SEC filing · Form F-3 | SEC EDGAR | +0.00% | +5.83% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ADAG section they belong to.
Where else ADAG is measured.
ADAG earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Adagene Inc. - ADS, each representing 1.25 ordinary shares's median reaction calculated?
Every labeled ADAG news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 146 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 54% of ADAG's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ADAG's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.